Supplementary Table 1. Patients with oropharyngeal squamous cell carcinoma and their tumour characteristics, treated with the intention to cure with oncological treatment separated in patients with available and not available pre-treatment biopsies.

oncological treatment separated in patients with available and not  Patient charachteristics		OSCC patients with pre-treatment biopsies (N=439)		OSCC patients without pre-treatment biopsies (N=45)		All identified OSCC patients, treated with the intention to cure (N=484)		p value	
			N	%	N	%	N	%	
Age	Mean (years)		61		61		61		
	Median (years)		60		61		60		
	Range (years)		30-90		40-93		30-93		ns
	Inter-quartile range (years)		54-67		53-69		54-68		
Diagnosis	malignant neoplasm of the base of tongue (C01.9)		103	24%	9	20%	112	23%	
	malignant neoplasm of the palate (C05.0-9)		22	5.0%	1	2.7%	23	4.8%	% ns
	malignant neoplasm of the tonsil (C09.0-9)		283	65%	32	71%	315	65%	115
	malignant neoplasm of the oropharynx (C10.0-9)		31	7.1%	3	6.7%	34	7.0%	
	female		119	27%	11	24%	130	27%	
Sex	male		320	73%	34	76%	354	73%	ns
	T1		94	21%	13	29%	107	22%	
	T2		153	35%	14	31%	167	35%	
Tumour si	ze 73		97	22%	7	16%	104	21%	ns
	T4		95	22%	11	24%	106	22%	
Nodal disease	NO		103	23%	11	24%	114	24%	
	N1		87	20%	9	20%	96	20%	
	N2a		60	14%	7	16%	67	14%	
	se N2b		117	27%	11	24%	128	26%	ns
	N2c		51	12%	5	11%	56	12%	
	N3		18	4.1%	2	4.4%	20	4.0%	
	NX		3	0.68%	0	0%	3	1.0%	
Distant metastasis	М0		429	98%	44	98%	473	98%	
	M1		3	0.68%	0	0%	3	1.0%	ns
	MX		7	1.6%	1	2.2%	8	2.0%	
Tumour Stage	1		14	3.2%	2	4.4%	16	3.0%	
	II .		36	8.2%	5	11%	41	8.0%	
	III		109	25%	9	20%	118	24%	
	ge IVa		251	57%	27	60%	278	57%	ns
	IVb		26	5.9%	2	4.4%	28	6.0%	
	IVc		3	0.68%	0	0%	3	1.0%	
Treatment	Induction chemotherapy	conventional	231	53%	3	7.0%	234	48%	
	and radiation	accelerated	72	16%	10	22%	82	17%	
	Radiation and concomittant	accelerated	0	0%	0	0%	0	0%	
	cisplatin	conventional	0	0%	1	2.0%	1	0%	0.007
		conventional	37	8.4%	23	51%	60	12%	
	Radiation	accelerated	99	23%	8	18%	107	22%	
Brachytherapy boost	Not administered		342	78%	36	80%	378	78%	
	Administered		97	22%	9	20%	106	22%	ns
Concomittant Cetuximab	Not administered		390	89%	40	89%	430	89%	
	Administered		49	11%	5	11%	54	11%	ns
	Never		112	26%	14	31%	126	26%	
	Former (>15 years ago)		61	14%	6	13%	67	14%	
Smoking	Former (<15 years ago)		65	15%	11	24%	76	16%	ns
	Current upon diagnosis		201	46%	14	31%	215	44%	
			323	74%	32	710/	355	73%	
Survived 3 years after diagnosis						71%			ns
	no		116	26%	13	29%	129	27%	